Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway
- DOI
- 10.2174/0115680096488328260909072155
- Published
- 2026-09-22
- Container
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2174/0115680096488328260909072155,
title = {Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway},
author = {Mengfei Chen and Ting Xu and Huiting Peng and Hanshuang Cai and Yuchen Zhao and Xiying Li and Kaili Dong and Chuanfeng Liu and Jing Shi and Yuguo Liu},
year = {2026},
journal = {Current Cancer Drug Targets},
doi = {10.2174/0115680096488328260909072155},
url = {https://doi.org/10.2174/0115680096488328260909072155}
}RIS
TY - JOUR TI - Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway AU - Mengfei Chen AU - Ting Xu AU - Huiting Peng AU - Hanshuang Cai AU - Yuchen Zhao AU - Xiying Li AU - Kaili Dong AU - Chuanfeng Liu AU - Jing Shi AU - Yuguo Liu PY - 2026 JO - Current Cancer Drug Targets DO - 10.2174/0115680096488328260909072155 UR - https://doi.org/10.2174/0115680096488328260909072155 ER -
APA
Chen, M., Xu, T., Peng, H., Cai, H., Zhao, Y., Li, X., Dong, K., Liu, C., Shi, J., & Liu, Y. (2026). Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway. Current Cancer Drug Targets. https://doi.org/10.2174/0115680096488328260909072155
Source records
- crossref · retrieved 2026-09-26T04:07:09.638Z